drugset / Trial / NCT03207815

Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

NCT03207815

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis as measured by the percentage of participants failing treatment for active noninfectious uveitis by Week 24.

Timeline

Start
2017-07-26
Primary completion
2020-12-29
Completion
2021-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Filgotinib Small molecule 200 mg Oral
Background Prednisone Other / unclassified 60 mg Oral

Indications